Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
serlopitant
- Development stage
- Phase 3
- Lead developer
- Tigercat Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Serlopitant is a small molecule drug that acts as a highly selective antagonist of the neurokinin 1 (NK1) receptor, also known as the substance P receptor. It was originally developed by Merck and later licensed to Menlo Therapeutics for further development. Serlopitant has been investigated primarily for the treatment of pruritus (itch), particularly in conditions such as prurigo nodularis and chronic pruritus of unknown origin. The mechanism of action involves blocking the NK1 receptor, thereby inhibiting substance P-mediated signaling pathways implicated in itch transmission. Clinical trials have shown that serlopitant can significantly reduce itch intensity in patients with chronic refractory pruritic conditions and is generally well tolerated[2][4][5][6][7][8].
- Other names
- serlopitant
02
Targets
TACR1 (Neurokinin‑1 Receptor)
Beyond the preview
Go deeper on serlopitant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on serlopitant.